Haisco(SZ:002653) Xin Lang Cai Jing·2025-10-28 14:10Core Insights - The article highlights the significant changes in the stock positions of various funds managed by the company, particularly in the healthcare sector, indicating a strategic shift towards high-performing stocks [1] Group 1: Fund Performance - The stock position of the China Europe Medical Health fund reached a record high of 94.56% [1] - The China Europe Medical Innovation fund significantly increased its holdings in Kanglong Chemical [1] Group 2: Stock Adjustments - The China Europe Medical Health fund made its first purchase of Haisco and increased its holdings in Kanglong Chemical, Baillie Gifford, Kylin Pharmaceutical, Tigermed, and Xinlitai [1] - The China Europe Medical Innovation fund reduced its positions in several stocks, including 3SBio and Kanyin Biotech [1] - The China Europe Mingrui New Starting Point fund increased its investments in Yangguang Electric, New Yisheng, Zhongji Xuchuang, Tianfu Communication, Hanwha, and Industrial Fulian [1]